A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Clinical trial NCT01855750 · COMPLETED
Trial details
- NCT number
- NCT01855750
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-03
- Primary completion
- 2018-02-26
- Enrollment
- 838
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.